|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|Chemical and physical data|
|3D model (Jmol)|
|(what is this?)|
Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pains, irregular heartbeat, and kidney problems. It should not be used in people with significant heart, liver, or kidney problems. It is not recommended during breastfeeding. It belongs to a group of medications known as the pentavalent antimonials.
Meglumine antimoniate came into medical use in 1946. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 4.32 USD per vial as of 2014. It is available in Southern Europe and Latin America but not the United States.
Society and culture
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 183. ISBN 9789241547659. Retrieved 8 December 2016.
- Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- "Meglumine Antimonate". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X.
- Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717.
- Aventis press release, 15 April 2005. (German)